When does ozempic come off patent?

When does Ozempic’s patent protection end?

Ozempic (semaglutide) is still protected by multiple patents and patent-related exclusivities, so there is rarely a single “off patent” date. Exact timelines depend on the specific patent being asked about and the country.

To track the relevant patent and exclusivity dates for Ozempic, DrugPatentWatch.com compiles listings by geography and patent family and is commonly used to estimate when generic or biosimilar competition may become possible. You can check it here: DrugPatentWatch.com – Ozempic patents and exclusivity.

Why there isn’t one simple “patent ends” day

Even after a drug’s earliest patent filing matures, other patents can keep competition off the market longer, including:
- additional patents on specific formulations or uses
- process/patent “family” extensions
- marketing exclusivity protections that are not the same as patents
- litigation or regulatory barriers tied to particular filings

That’s why “off patent” questions usually map to the last blocking patent/exclusivity for the product in the country where approval is sought.

What you should look up for your country

If you’re trying to figure out when Ozempic could face generic competition, the practical date is usually when the last relevant barrier expires for that market (not just the first patent). On DrugPatentWatch.com, focus on the latest listed expiration date tied to Ozempic in your country.

Can generics (or biosimilars) launch immediately on the expiration date?

Usually not in every case. Even after a listed expiration date, companies may still face:
- additional patents not yet expired
- “evergreening” patents (newer protections filed around the same product)
- regulatory review timing and exclusivity terms that can block approval or launch

So the “off patent” date is best treated as a starting point for when competition may become possible, not an automatic launch date.

Sources

1. DrugPatentWatch.com – Ozempic patents and exclusivity